Coenzyme Q10 (CoQ10), a lipophilic substituted benzoquinone, is present in animal and plant cells. It is endogenously synthetized in every cell and involved in a variety of cellular processes. CoQ10 is an obligatory component of the respiratory chain in inner mitochondrial membrane. In addition, the presence of CoQ10 in all cellular membranes and in blood. It is the only endogenous lipid antioxidant. Moreover, it is an essential factor for uncoupling protein and controls the permeability transition pore in mitochondria. It also participates in extramitochondrial electron transport and controls membrane physicochemical properties. CoQ10 effects on gene expression might affect the overall metabolism. Primary changes in the energetic and antioxidant functions can explain its remedial effects. CoQ10 supplementation is safe and well-tolerated, even at high doses. CoQ10 does not cause any serious adverse effects in humans or experimental animals. New preparations of CoQ10 that are less hydrophobic and structural derivatives, like idebenone and MitoQ, are being developed to increase absorption and tissue distribution. The review aims to summarize clinical and experimental effects of CoQ10 supplementations in some neurological diseases such as migraine, Parkinson´s disease, Huntington´s disease, Alzheimer´s disease, amyotrophic lateral sclerosis, Friedreich´s ataxia or multiple sclerosis. Cardiovascular hypertension was included because of its central mechanisms controlling blood pressure in the brainstem rostral ventrolateral medulla and hypothalamic paraventricular nucleus. In conclusion, it seems reasonable to recommend CoQ10 as adjunct to conventional therapy in some cases. However, sometimes CoQ10 supplementations are more efficient in animal models of diseases than in human patients (e.g. Parkinson´s disease) or rather vague (e.g. Friedreich´s ataxia or amyotrophic lateral sclerosis).

Institute of Physiology Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

ACAR A, UGUR CEVIK M, EVLIYAOGLU O, UZAR E, TAMAM Y, ARIKANOGLU A, YUCEL Y, VAROL S, ONDER H, TAŞDEMIR N. Evaluation of serum oxidant/antioxidant balance in multiple sclerosis. Acta Neurol Belg. 2012;112:275–280. doi: 10.1007/s13760-012-0059-4. PubMed DOI

AGMO HERNÁNDEZ V, ERIKSSON EK, EDWARDS K. Ubiquinone-10 alters mechanical properties and increases stability of phospholipid membranes. Biochim Biophys Acta. 2015;1848:2233–2243. doi: 10.1016/j.bbamem.2015.05.002. PubMed DOI

ALCÁZAR-FABRA M, TREVISSON E, BREA-CALVO G. Clinical syndromes associated with coenzyme Q10 deficiency. Essays Biochem. 2018;62:377–398. doi: 10.1042/EBC20170107. PubMed DOI

ALZHEIMER’S ASSOCIATION. Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9:208–245. doi: 10.1016/j.jalz.2013.02.003. PubMed DOI

ARI C, POFF AM, HELD HE, LANDON CS, GOLDHAGEN CR, MAVROMATES N, D’AGOSTINO DP. Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PloS One. 2014;9:e103526. doi: 10.1371/journal.pone.0103526. PubMed DOI PMC

ARMON-OMER A, WALDMAN C, SIMAAN N, NEUMAN H, TAMIR S, SHAHIEN R. New insights on the nutrition status and antioxidant capacity in multiple sclerosis patients. Nutrients. 2019;11:427. doi: 10.3390/nu11020427. PubMed DOI PMC

ARTUCH R, ARACIL A, MAS A, COLOMÉ C, RISSECH M, MONRÓS E, PINEDA M. Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics. 2002;33:190–193. doi: 10.1055/s-2002-34494. PubMed DOI

ATTIA HN, MAKLAD YA. Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson’s disease in experimental animals. Behav Pharmacol. 2018;29:79–86. doi: 10.1097/FBP0000000000000342. PubMed DOI

ATWOOD CS, HUANG X, MOIR RD, TANZI RE, BUSH AI. Role of free radicals and metal ions in the pathogenesis of Alzheimer’s disease. Met Ions Biol Syst. 1999;36:309–364. PubMed

AWAD AM, BRADLEY MC, FERNÁNDEZ-DEL-RÍO L, NAG A, TSUI HS, CLARKE CF. Coenzyme Q10 deficiencies: pathways in yeast and humans. Essays Biochem. 2018;62:361–376. doi: 10.1042/EBC20170106. PubMed DOI PMC

BAGUR MJ, MURCIA MA, JIMÉNEZ-MONREAL AM, TUR JA, BIBILONI MM, ALONSO GL, MARTÍNEZ-TOMÉ M. Influence of diet in multiple sclerosis: A systematic review. Adv Nutr. 2017;8:463–472. doi: 10.3945/an.116.014191. PubMed DOI PMC

BAHADORANI S, HILLIKER AJ. Antioxidants cannot suppress the lethal phenotype of a Drosophila melanogaster model of Huntington’s disease. Genome. 2008;51:392–395. doi: 10.1139/G08-012. PubMed DOI

BALOYANNIS SJ. Mitochondrial alterations in Alzheimer’s disease. J Alzheimers Dis. 2006;9:119–126. doi: 10.3233/jad-2006-9204. PubMed DOI

BALOYANNIS SJ. Dendritic pathology in Alzheimer’s disease. J Neurol Sci. 2009;283:153–157. doi: 10.1016/j.jns.2009.02.370. PubMed DOI

BARBER SC, SHAW PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48:629–641. doi: 10.1016/j.freeradbiomed.2009.11.018. PubMed DOI

BARNES DE, YAFFE K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10:819–828. doi: 10.1016/S1474-4422(11)70072-2. PubMed DOI PMC

BATTINO M, FERRI E, GORINI A, VILLA RF, RODRIGUEZ HUERTAS JF, FIORELLA P, GENOVA ML, LENAZ G, MARCHETTI M. Natural distribution and occurrence of coenzyme Q homologues. Membr Biochem. 1990;9:179–190. https://org.doi/10.3109/09687689009025839 . PubMed DOI

BATTINO M, GORINI A, VILLA RF, GENOVA ML, BOVINA C, SASSI S, LITTARRU GP, LENAZ G. Coenzyme Q content in synaptic and non-synaptic mitochondria from different brain regions in the ageing rat. Mech Ageing Dev. 1995;78:173–187. https://org.doi:10/1016/0047-6374(94)01535-t . PubMed

BEAL MF, MATTHEWS RT, TIELEMAN A, SHULTS CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783:109–114. doi: 10.1016/s0006-8993(97)01192-x. PubMed DOI

BELOUSOVA M, TOKAREVA OG, GORODETSKAYA E, KALENIKOVA EI, MEDVEDEV OS. Intravenous treatment with coenzyme Q10 improves neurological outcome and reduces infarct volume after transient focal brain ischemia in rats. J Cardiovasc Pharmacol. 2016;67:103–109. doi: 10.1097/FJC.0000000000000320. PubMed DOI

BERGAMASCO B, SCARZELLA L, LA COMMARE P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol. 1994;9:161–168. PubMed

BEYER RE, BURNETT BA, CARTWRIGHT KJ, EDINGTON DW, FALZON MJ, KREITMAN KR, KUHN TW, RAMP BJ, RHEE SY, ROSENWASSER MJ, STEIN M, AN LC. Tissue coenzyme Q (ubiquinone) and protein concentrations over the life span of the laboratory rat. Mech Ageing Dev. 1985;32:267–281. doi: 10.1016/0047-6374(85)90085-5. PubMed DOI

BHAGAVAN HN, CHOPRA RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006;40:445–453. doi: 10.1080/10715760600617843. PubMed DOI

BHAGAVAN HN, CHOPRA RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007;7(Suppl):S78–S88. doi: 10.1016/j.mito.2007.03.003. PubMed DOI

BINDOFF LA, BIRCH-MACHIN MA, CARTLIDGE NE, PARKER WD, JR, TURNBULL DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson’s disease. J Neurol Sci. 1991;104:203–208. doi: 10.1016/0022-510x(91)90311-t. PubMed DOI

BLAKE RL, HALL JG, RUSSELL ES. Mitochondrial proline dehydrogenase deficiency in hyperprolinemic PRO/Re mice: genetic and enzymatic analyses. Biochem Genet. 1976;14:739–757. doi: 10.1007/BF00485338. PubMed DOI

BOND L, BERNHARDT K, MADRIA P, SORRENTINO K, SCELSI H, MITCHELL CS. A metadata analysis of oxidative stress etiology in preclinical amyotrophic lateral sclerosis: Benefits of antioxidant therapy. Front Neurosci. 2018;12:10. doi: 10.3389/fnins.2018.00010. PubMed DOI PMC

BONO-YAGÜE J, GÓMEZ-ESCRIBANO AP, MILLÁN JM, VÁZQUEZ-MANRIQUE RP. Reactive species in Huntington disease: are they really the radicals you want to catch? Antioxidants (Basel) 2020;9:577. doi: 10.3390/antiox9070577. PubMed DOI PMC

BOROWY-BOROWSKI H, SODJA C, DOCHERTY J, WALKER PR, SIKORSKA M. Unique technology for solubilization and delivery of highly lipophilic bioactive molecules. J Drug Target. 2004;12:415–424. doi: 10.1080/10611860412331285233. PubMed DOI

BRANDSEMA JF, STEPHENS D, HARTLEY J, YOON G. Intermediate-dose idebenone and quality of life in Friedreich ataxia. Pediatr Neurol. 2010;42:338–342. doi: 10.1016/j.pediatrneurol.2010.01.004. PubMed DOI

BRIÈRE JJ, SCHLEMMER D, CHRETIEN D, RUSTIN P. Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem Biophys Res Commun. 2004;316:1138–1142. doi: 10.1016/j.bbrc.2004.03.002. PubMed DOI

BÜRK K. Friedreich Ataxia: current status and future prospects. Cerebellum Ataxias. 2017;4:4. doi: 10.1186/s40673-017-0062. PubMed DOI PMC

BUYSE G, MERTENS L, DI SALVO G, MATTHIJS I, WEIDEMANN F, EYSKENS B, GOOSSENS W, GOEMANS N, SUTHERLAND GR, VAN HOVE JL. Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology. 2003;60:1679–1681. doi: 10.1212/01.wnl.0000068549.52812.0f. PubMed DOI

CABONI P, SHERER TB, ZHANG N, TAYLOR G, NA HM, GREENAMYRE JT, CASIDA JE. Rotenone, deguelin, their metabolites, and the rat model of Parkinson’s disease. Chem Res Toxicol. 2004;17:1540–1548. doi: 10.1021/tx049867r. PubMed DOI

CABRINI L, BARZANTI V, CIPOLLONE M, FIORENTINI D, GROSSI G, TOLOMELLI B, ZAMBONIN L, LANDI L. Antioxidants and total peroxyl radical-trapping ability of olive and seed oils. J Agric Food Chem. 2001;49:6026–6032. doi: 10.1021/jf010837t. PubMed DOI

CAMPBELL GR, KRAYTSBERG Y, KRISHNAN KJ, OHNO N, ZIABREVA I, REEVE A, TRAPP BD, NEWCOMBE J, REYNOLDS R, LASSMANN H, KHAPKO K, TURNBULL DM, MAHAD DJ. Clonally expanded mitochondrial DNA deletions within the choroid plexus in multiple sclerosis. Acta Neuropathol. 2012;124:209–220. doi: 10.1007/s00401-012-1001-9. PubMed DOI PMC

CANNON JR, TAPIAS V, NA HM, HONICK AS, DROLET RE, GREENAMYRE JT. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis. 2009;34:279–290. doi: 10.1016/j.nbd.2009.01.016. PubMed DOI PMC

CAPALDI RA. Arrangement of proteins in the mitochondrial inner membrane. Biochim Biophys Acta. 1982;694:291–306. doi: 10.1016/0304-4157(82)90009-0. PubMed DOI

CHAN SH, WU KL, CHANG AY, TAI MH, CHAN JY. Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. Hypertension. 2009;53:217–227. doi: 10.1161/HYPERTENSIONAHA.108.116905. PubMed DOI

CHOI IY, LEE P, ADANY P, HUGHES AJ, BELLISTON S, DENNEY DR, LYNCH SG. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis. Mult Scler. 2018;24:1029–1038. doi: 10.1177/1352458517711568. PubMed DOI PMC

CICCHETTI F, LAPOINTE N, ROBERGE-TREMBLAY A, SAINT-PIERRE M, JIMENEZ L, FICKE BW, GROSS RE. Systemic exposure to paraquat and maneb models early Parkinson’s disease in young adult rats. Neurobiol Dis. 2005;20:360–371. doi: 10.1016/j.nbd.2005.03.018. PubMed DOI

CLEREN C, YANG L, LORENZO B, CALINGASAN NY, SCHOMER A, SIRECI A, WILLE EJ, BEAL MF. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem. 2008;104:1613–1621. doi: 10.1111/j.1471-4159.2007.05097.x. PubMed DOI

COOPER JM, KORLIPARA LV, HART PE, BRADLEY JL, SCHAPIRA AH. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008;15:1371–1379. doi: 10.1111/j.1468-1331.2008.02318.x. PubMed DOI

CRANE FL. Comments on the discovery of coenzyme Q: a commentary on ‘Isolation of a quinone from beef heart mitochondria’. Biochim Biophys Acta. 1989;1000:358–361. doi: 10.1016/s0006-3002(89)80030-7. PubMed DOI

CRANE FL, HATEFI Y, LESTER RL, WIDMER C. Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta. 1957;25:220–221. doi: 10.1016/0006-3002(57)90457-2. PubMed DOI

DAHRI M, TARIGHAT-ESFANJANI A, ASGHARI-JAFARABADI M, HASHEMILAR M. Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutr Neurosci. 2019;22:607–615. doi: 10.1080/1028415X.2017.1421039. PubMed DOI

DE BUSTOS F, JIMÉNEZ-JIMÉNEZ FJ, MOLINA JA, GÓMEZ-ESCALONILLA C, DE ANDRÉS C, DEL HOYO P, ZURDO M, TALLÓN-BARRANCO A, BERBEL A, PORTA-ETESSAM J, PARRILLA G, ARENAS J. Serum levels of coenzyme Q10 in patients with multiple sclerosis. Acta Neurol Scand. 2000;101:209–211. doi: 10.1034/j.1600-0404.2000.101003209.x. PubMed DOI

DE BUSTOS F, MOLINA JA, JIMÉNEZ-JIMÉNEZ FJ, GARCÍA-REDONDO A, GÓMEZ-ESCALONILLA C, PORTA-ETESSAM J, BERBEL A, ZURDO M, BARCENILLA B, PARRILLA G, ENRIQUEZ-DE-SALAMANCA R, ARENAS J. Serum levels of coenzyme Q10 in patients with Alzheimer’s disease. J Neural Transm (Vienna) 2000;107:233–239. doi: 10.1007/s007020050019. PubMed DOI

DESBATS MA, LUNARDI G, DOIMO M, TREVISSON E, SALVIATI L. Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency. J Inherit Metab Dis. 2015;38:145–156. doi: 10.1007/s10545-014-9749-9. PubMed DOI

DI MARCO LY, VENNERI A, FARKAS E, EVANS PC, MARZO A, FRANGI AF. Vascular dysfunction in the pathogenesis of Alzheimer’s disease--A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015;82:593–606. doi: 10.1016/j.nbd.2015.08.014. PubMed DOI

DI PROSPERO NA, BAKER A, JEFFRIES N, FISCHBECK KH. Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6:878–886. doi: 10.1016/S1474-4422(07)70220-X. PubMed DOI

DUBERLEY KE, HEALES SJ, ABRAMOV AY, CHALASANI A, LAND JM, RAHMAN S, HARGREAVES IP. Effect of coenzyme Q10 supplementation on mitochondrial electron transport chain activity and mitochondrial oxidative stress in coenzyme Q10 deficient human neuronal cells. Int J Biochem Cell Biol. 2014;50:60–63. doi: 10.1016/j.biocel.2014.02.003. PubMed DOI

DUMONT M, KIPIANI K, YU F, WILLE E, KATZ M, CALINGASAN NY, GOURAS GK, LIN MT, BEAL MF. Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis. 2011;27:211–223. doi: 10.3233/JAD-2011-110209. PubMed DOI PMC

ECHTAY KS, WINKLER E, KLINGENBERG M. Coenzyme Q is an obligatory cofactor for uncoupling protein function. Nature. 2000;408(6812):609–613. doi: 10.1038/35046114. PubMed DOI

EHRENHAUS MASOTTA N, HÖCHT C, CONTIN M, LUCANGIOLI S, ROJAS AM, TRIPODI VP. Bioavailability of coenzyme Q10 loaded in an oleogel formulation for oral therapy: Comparison with a commercial-grade solid formulation. Int J Pharm. 2020;582:119315. doi: 10.1016/j.ijpharm.2020.119315. PubMed DOI

ELIPENAHLI C, STACK C, JAINUDDIN S, GERGES M, YANG L, STARKOV A, BEAL MF, DUMONT M. Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice. J Alzheimers Dis. 2012;28:173–182. doi: 10.3233/JAD-2011-111190. PubMed DOI PMC

ELMBERGER PG, KALÈN A, APPELKVIST EL, DALLNER G. In vitro and in vivo synthesis of dolichol and other main mevalonate products in various organs of the rat. Eur J Biochem. 1987;168:1–11. doi: 10.1111/j.1432-1033.1987.tb13379.x. PubMed DOI

ESPOSTI MD, NGO A, GHELLI A, BENELLI B, CARELLI V, MCLENNAN H, LINNANE AW. The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys. 1996;330:395–400. https://doi.org10.1006/abbi.1996.0267 . PubMed

ESSA MM, MOGHADAS M, BA-OMAR T, WALID QORONFLEH M, GUILLEMIN GJ, MANIVASAGAM T, JUSTIN-THENMOZHI A, RAY B, BHAT A, CHIDAMBARAM SB, FERNANDES AJ, SONG BJ, AKBAR M. Protective effects of antioxidants in Huntington’s disease: an extensive review. Neurotox Res. 2019;35:739–774. https://doi,org/10.1007/s12640-018-9989-9 . PubMed DOI

EVANS DR, GUY HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem. 2004;279:33035–33038. doi: 10.1074/jbc.R400007200. PubMed DOI

EVANS E, PICCIO L, CROSS AH. Use of vitamins and dietary supplements by patients with multiple sclerosis: A review [published correction appears in JAMA Neurol 75: 1028, 2018] JAMA Neurol. 2018;75:1013–1021. doi: 10.1001/jamaneurol.2018.0611. PubMed DOI

FALKENBURGER BH, SARIDAKI T, DINTER E. Cellular models for Parkinson’s disease. J Neurochem. 2016;139(Suppl 1):121–130. doi: 10.1111/jnc.13618. PubMed DOI

FAN L, FENG Y, CHEN GC, QIN LQ, FU CL, CHEN LH. Effects of coenzyme Q10 supplementation on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2017;119:128–136. doi: 10.1016/j.phrs.2017.01.032. PubMed DOI

FATO R, BERTOLI E, PARENTI CASTELLI G, LENAZ G. Fluidizing effect of endogenous ubiquinone in bovine heart mitochondrial membranes. FEBS Lett. 1984;172:6–10. doi: 10.1016/0014-5793(84)80861-3. PubMed DOI

FERRANTE RJ, ANDREASSEN OA, DEDEOGLU A, FERRANTE KL, JENKINS BG, HERSCH SM, BEAL MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci. 2002;22:1592–1599. doi: 10.1523/JNEUROSCI.22-05-01592.2002. PubMed DOI PMC

FERRANTE KL, SHEFNER J, ZHANG H, BETENSKY R, O’BRIEN M, YU H, FANTASIA M, TAFT J, BEAL MF, TRAYNOR B, NEWHALL K, DONOFRIO P, CARESS J, ASHBURN C, FREIBERG B, O’NEILL C, PALADENECH C, WALKER T, PESTRONK A, ABRAMS B, FLORENCE J, RENNA R, SCHIERBECKER J, MALKUS B, CUDKOWICZ M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005;65:1834–1836. doi: 10.1212/01.wnl.0000187070.35365.d7. PubMed DOI

FETONI AR, DE BARTOLO P, ERAMO SL, ROLESI R, PACIELLO F, BERGAMINI C, FATO R, PALUDETTI G, PETROSINI L, TROIANI D. Noise-induced hearing loss (NIHL) as a target of oxidative stress-mediated damage: cochlear and cortical responses after an increase in antioxidant defense. J Neurosci. 2013;33:4011–4023. doi: 10.1523/JNEUROSCI.2282-12.2013. PubMed DOI PMC

FIŠAR Z, HANSÍKOVÁ H, KŘÍŽOVÁ J, JIRÁK R, KITZLEROVÁ E, ZVĚŘOVÁ M, HROUDOVÁ J, WENCHICH L, ZEMAN J, RABOCH J. Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer’s disease and depressive disorder. Mitochondrion. 2019;48:67–77. doi: 10.1016/j.mito.2019.07.013. PubMed DOI

FONTAINE E, ICHAS F, BERNARDI P. A ubiquinone-binding site regulates the mitochondrial permeability transition pore. J Biol Chem. 1998;273:25734–25740. doi: 10.1074/jbc.273.40.25734. PubMed DOI

FRERMAN FE. Acyl-CoA dehydrogenases, electron transfer flavoprotein and electron transfer flavoprotein dehydrogenase. Biochem Soc Trans. 1988;16:416–418. doi: 10.1042/bst0160416. PubMed DOI

GALASKO DR, PESKIND E, CLARK CM, QUINN JF, RINGMAN JM, JICHA GA, COTMAN C, COTTRELL B, MONTINE TJ, THOMAS RG, AISEN P Alzheimer’s Disease Cooperative Study. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012;69:836–841. doi: 10.1001/archneurol.2012.85. PubMed DOI PMC

GAO HL, YU XJ, QI J, YI QY, JING WH, SUN WY, CUI W, MU JJ, YUAN ZY, ZHAO XF, LIU KL, ZHU GQ, SHI XL, LIU JJ, KANG YM. Oral CoQ10 attenuates high salt-induced hypertension by restoring neurotransmitters and cytokines in the hypothalamic paraventricular nucleus. Sci Rep. 2016;6:30301. doi: 10.1038/srep30301. PubMed DOI PMC

GAUL C, DIENER HC, DANESCH U MIGRAVENT® STUDY GROUP. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain. 2015;16:516. doi: 10.1186/s10194-015-0516-6. PubMed DOI PMC

GENOVA ML, LENAZ G. New developments on the functions of coenzyme Q in mitochondria. Biofactors. 2011;37:330–354. doi: 10.1002/biof.168. PubMed DOI

GENOVA ML, LENAZ G. Functional role of mitochondrial respiratory supercomplexes. Biochim Biophys Acta. 2014;1837:427–443. doi: 10.1016/j.bbabio.2013.11.002. PubMed DOI

GIAVAROTTI L, SIMON KA, AZZALIS LA, FONSECA FL, LIMA AF, FREITAS MC, BRUNIALTI MK, SALOMÃO R, MOSCARDI AA, MONTAÑO MB, RAMOS LR, JUNQUEIRA VB. Mild systemic oxidative stress in the subclinical stage of Alzheimer’s disease. Oxid Med Cell Longev. 2013;2013:609019. doi: 10.1155/2013/609019. PubMed DOI PMC

GILLE L, NOHL H. The existence of a lysosomal redox chain and the role of ubiquinone. Arch Biochem Biophys. 2000;375:347–354. doi: 10.1006/abbi.1999.1649. PubMed DOI

GIRONI M, BORGIANI B, MARIANI E, CURSANO C, MENDOZZI L, CAVARRETTA R, SARESELLA M, CLERICI M, COMI G, ROVARIS M, FURLAN R. Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. J Immunol Res. 2014;2014:961863. doi: 10.1155/2014/961863. PubMed DOI PMC

GUEVEN N, RAVISHANKAR P, ERI R, RYBALKA E. Idebenone: When an antioxidant is not an antioxidant. Redox Biol. 2021;38:101812. doi: 10.1016/j.redox.2020.101812. PubMed DOI PMC

GUEVEN N, WOOLLEY K, SMITH J. Border between natural product and drug: comparison of the related benzoquinones idebenone and coenzyme Q10. Redox Biol. 2015;4:289–295. doi: 10.1016/j.redox.2015.01.009. PubMed DOI PMC

GUILBOT A, BANGRATZ M, AIT ABDELLAH S, LUCAS C. A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study. BMC Complement Altern Med. 2017;17:433. doi: 10.1186/s12906-017-1933-7. PubMed DOI PMC

GUPTA A, KOOCHAKZADEH S, NGUYEN SA, BRENNAN EA, MEYER TA, LAMBERT PR. Pharmacological prevention of noise-induced hearing loss: A systematic review. Otol Neurotol. 2021;42:2–9. doi: 10.1097/MAO.0000000000002858. PubMed DOI PMC

GUTZMANN H, HADLER D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl. 1998;54:301–310. doi: 10.1007/978-3-7091-7508-8_30. PubMed DOI

GUYENET PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335–346. doi: 10.1038/nrn1902. PubMed DOI

HAAS RH, NASIRIAN F, NAKANO K, WARD D, PAY M, HILL R, SHULTS CW. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson’s disease. Ann Neurol. 1995;37:714–722. doi: 10.1002/ana.410370604. PubMed DOI

HAIDER L, FISCHER MT, FRISCHER JM, BAUER J, HÖFTBERGER R, BOTOND G, ESTERBAUER H, BINDER CJ, WITZTUM JL, LASSMANN H. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134:1914–1924. doi: 10.1093/brain/awr128. PubMed DOI PMC

HAJIHASHEMI P, ASKARI G, KHORVASH F, REZA MARACY M, NOURIAN M. The effects of concurrent coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial. Cephalalgia. 2019;39:648–654. doi: 10.1177/0333102418821661. PubMed DOI

HAMADJIDA A, FROUNI I, KWAN C, HUOT P. Classic animal models of Parkinson’s disease: a historical perspective. Behav Pharmacol. 2019;30:291–310. doi: 10.1097/FBP.0000000000000441. PubMed DOI

HARGREAVES IP, LANE A, SLEIMAN PM. The coenzyme Q10 status of the brain regions of Parkinson’s disease patients. Neurosci Lett. 2008;447:17–19. doi: 10.1016/j.neulet.2008.09.069. PubMed DOI

HART PE, LODI R, RAJAGOPALAN B, BRADLEY JL, CRILLEY JG, TURNER C, BLAMIRE AM, MANNERS D, STYLES P, SCHAPIRA AH, COOPER JM. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol. 2005;62:621–626. doi: 10.1001/archneur.62.4.621. PubMed DOI

HATHCOCK JN, SHAO A. Risk assessment for coenzyme Q10 (Ubiquinone) Regul Toxicol Pharmacol. 2006;45:282–288. doi: 10.1016/j.yrtph.2006.05.006. PubMed DOI

HERSHEY AD, POWERS SW, VOCKELL AL, LECATES SL, ELLINOR PL, SEGERS A, BURDINE D, MANNING P, KABBOUCHE MA. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007;47:73–80. doi: 10.1111/j.1526-4610.2007.00652.x. PubMed DOI

HICKEY MA, ZHU C, MEDVEDEVA V, FRANICH NR, LEVINE MS, CHESSELET MF. Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington’s disease. Mol Cell Neurosci. 2012;49:149–157. doi: 10.1016/j.mcn.2011.10.007. PubMed DOI PMC

HIDAKA T, FUJII K, FUNAHASHI I, FUKUTOMI N, HOSOE K. Safety assessment of coenzyme Q10 (CoQ10) Biofactors. 2008;32:199–208. doi: 10.1002/biof.5520320124. PubMed DOI

HIROOKA Y, SAGARA Y, KISHI T, SUNAGAWA K. Oxidative stress and central cardiovascular regulation. Pathogenesis of hypertension and therapeutic aspects. Circ J. 2010;74:827–835. doi: 10.1253/circj.cj-10-0153. PubMed DOI

HO MJ, LI EC, WRIGHT JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2016;3:CD007435. doi: 10.1002/14651858.CD007435.pub3. PubMed DOI PMC

HUNTINGTON STUDY GROUP. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397–404. doi: 10.1212/wnl.57.3.397. PubMed DOI

HUNTINGTON STUDY GROUP PRE2CARE INVESTIGATORS. HYSON HC, KIEBURTZ K, ET AL. Safety and tolerability of high-dosage coenzyme Q10 in Huntington’s disease and healthy subjects. Mov Disord. 2010;25:1924–1928. doi: 10.1002/mds.22408. PubMed DOI

IKEMATSU H, NAKAMURA K, HARASHIMA S, FUJII K, FUKUTOMI N. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial. Regul Toxicol Pharmacol. 2006;44:212–228. doi: 10.1016/j.yrtph.2005.12.002. PubMed DOI

JABER S, POLSTER BM. Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? J Bioenerg Biomembr. 2015;47:111–118. doi: 10.1007/s10863-014-9571-y. PubMed DOI PMC

JACKSON-LEWIS V, PRZEDBORSKI S. Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc. 2007;2:141–151. doi: 10.1038/nprot.2006.342. PubMed DOI

JAMES AM, COCHEMÉ HM, SMITH RA, MURPHY MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem. 2005;280:21295–21312. doi: 10.1074/jbc.M501527200. PubMed DOI

JIMÉNEZ-JIMÉNEZ FJ, MOLINA JA, DE BUSTOS F, GARCÍA-REDONDO A, GÓMEZ-ESCALONILLA C, MARTÍNEZ-SALIO A, BERBEL A, CAMACHO A, ZURDO M, BARCENILLA B, ENRÍQUEZ DE SALAMANCA R, ARENAS J. Serum levels of coenzyme Q10 in patients with Parkinson’s disease. J Neural Transm (Vienna) 2000;107:177–181. doi: 10.1007/s007020050015. PubMed DOI

JOSHI G, BEKIER ME, 2ND, WANG Y. Golgi fragmentation in Alzheimer’s disease. Front Neurosci. 2015;9:340. doi: 10.3389/fnins.2015.00340. PubMed DOI PMC

KAGAN T, DAVIS C, LIN L, ZAKERI Z. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann N Y Acad Sci. 1999;887:31–47. doi: 10.1111/j.1749-6632.1999.tb07920.x. PubMed DOI

KALÉN A, APPELKVIST EL, DALLNER G. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989;24:579–584. doi: 10.1007/BF02535072. PubMed DOI

KAMEI M, FUJITA T, KANBE T, SASAKI K, OSHIBA K, OTANI S, MATSUI-YUASA I, MORISAWA S. The distribution and content of ubiquinone in foods. Int J Vit Nutr Res. 1986;56:57–63. PubMed

KAMZALOV S, SUMIEN N, FORSTER MJ, SOHAL RS. Coenzyme Q intake elevates the mitochondrial and tissue levels of coenzyme Q and alpha-tocopherol in young mice. J Nutr. 2003;133:3175–3180. doi: 10.1093/jn/133.10.3175. PubMed DOI

KASPAROVÁ S, SUMBALOVÁ Z, BYSTRICKÝ P, KUCHARSKÁ J, LIPTAJ T, MLYNÁRIK V, GVOZDJÁKOVÁ A. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington’s disease. Neurochem Int. 2006;48:93–99. doi: 10.1016/j.neuint.2005.09.002. PubMed DOI

KAUFMANN P, THOMPSON JL, LEVY G, BUCHSBAUM R, SHEFNER J, KRIVICKAS LS, KATZ J, ROLLINS Y, BAROHN RJ, JACKSON CE, TIRYAKI E, LOMEN-HOERTH C, ARMON C, TANDAN R, RUDNICKI SA, REZANIA K, SUFIT R, PIORO EP, MONTES J, ARBING R, VECCHIO D, BARSDORF A, MITSUMOTO H, LEVIN B QALS STUDY GROUP. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–244. doi: 10.1002/ana.21743. PubMed DOI PMC

KETTAWAN A, KUNTHIDA C, TAKAHASHI T, KISHI T, CHIKAZAWA J, SAKATA Y, YANO E, WATABE K, YAMAMOTO Y, OKAMOTO T. The quality control assessment of commercially available coenzyme Q10-containing dietary and health supplements in Japan. J Clin Biochem Nutr. 2007;41:124–131. doi: 10.3164/jcbn.2007017. PubMed DOI PMC

KHALILIAN B, MADADI S, FATTAHI N, ABOUHAMZEH B. Coenzyme Q10 enhances remyelination and regulate inflammation effects of cuprizone in corpus callosum of chronic model of multiple sclerosis. J Mol Histol. 2021;52:125–134. doi: 10.1007/s10735-020-09929-x. PubMed DOI

KIMURA Y, HIROOKA Y, SAGARA Y, ITO K, KISHI T, SHIMOKAWA H, TAKESHITA A, SUNAGAWA K. Overexpression of inducible nitric oxide synthase in rostral ventrolateral medulla causes hypertension and sympathoexcitation via an increase in oxidative stress. Circ Res. 2005;96:252–260. doi: 10.1161/01.RES.0000152965.75127.9d. PubMed DOI

KISHI T, HIROOKA Y, KIMURA Y, ITO K, SHIMOKAWA H, TAKESHITA A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation. 2004;109:2357–2362. doi: 10.1161/01.CIR.0000128695.49900.12. PubMed DOI

KITANO M, WATANABE D, ODA S, KUBO H, KISHIDA H, FUJII K, KITAHARA M, HOSOE K. Subchronic oral toxicity of ubiquinol in rats and dogs. Int J Toxicol. 2008;27:189–215. doi: 10.1080/10915810801978060. PubMed DOI

KONNO S, HIROOKA Y, KISHI T, SUNAGAWA K. Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats. J Hypertens. 2012;30:1992–1999. doi: 10.1097/HJH.0b013e328357fa98. PubMed DOI

KOROSHETZ WJ, JENKINS BG, ROSEN BR, BEAL MF. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol. 1997;41:160–165. doi: 10.1002/ana.410410206. PubMed DOI

KRIGE D, CARROLL MT, COOPER JM, MARSDEN CD, SCHAPIRA AH. Platelet mitochondrial function in Parkinson’s disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol. 1992;32:782–788. doi: 10.1002/ana.410320612. PubMed DOI

KUBO H, FUJII K, KAWABE T, MATSUMOTO S, KISHIDA H, HOSOE K. Food content of ubiquinol-10 and ubiquinone-10 in the Japanese diet. J Food Compost Anal. 2008;21:199–210.

KUMAR A, KUMAR V, SINGH K, KUMAR S, KIM YS, LEE YM, KIM JJ. Therapeutic advances for Huntington’s disease. Brain Sci. 2020;10:43. doi: 10.3390/brainsci10010043. PubMed DOI PMC

KWONG LK, KAMZALOV S, REBRIN I, BAYNE AC, JANA CK, MORRIS P, FORSTER MJ, SOHAL RS. Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic Biol Med. 2002;33:627–638. doi: 10.1016/s0891-5849(02)00916-4. PubMed DOI

LASS A, FORSTER MJ, SOHAL RS. Effects of coenzyme Q10 and alpha-tocopherol administration on their tissue levels in the mouse: elevation of mitochondrial alpha-tocopherol by coenzyme Q10. Free Radic Biol Med. 1999;26:1375–1382. doi: 10.1016/s0891-5849(98)00330-x. PubMed DOI

LEVY G, KAUFMANN P, BUCHSBAUM R, MONTES J, BARSDORF A, ARBING R, BATTISTA V, ZHOU X, MITSUMOTO H, LEVIN B, THOMPSON JLP. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006;66:660–663. doi: 10.1212/01.wnl.0000201182.60750.66. PubMed DOI

LI X, ZHAN J, HOU Y, CHEN S, HOU Y, XIAO Z, LUO D, LIN D. Coenzyme Q10 suppresses oxidative stress and apoptosis via activating the Nrf-2/NQO-1 and NF-κB signaling pathway after spinal cord injury in rats. Am J Transl Res. 2019;11:6544–6552. PubMed PMC

LIN P, LIU J, REN M, JI K, LI L, ZHANG B, GONG Y, YAN C. Idebenone protects against oxidized low density lipoprotein induced mitochondrial dysfunction in vascular endothelial cells via GSK3β/β-catenin signalling pathways. Biochem Biophys Res Commun. 2015;465:548–555. doi: 10.1016/j.bbrc.2015.08.058. PubMed DOI

LINNANE AW, KIOS M, VITETTA L. Coenzyme Q(10)--its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome. Mitochondrion. 2007;7(Suppl):S51–S61. doi: 10.1016/j.mito.2007.03.005. PubMed DOI

LIU ZX, ARTMANN C. Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Altern Ther Health Med. 2009;15:42–46. PubMed

LODI R, HART PE, RAJAGOPALAN B, TAYLOR DJ, CRILLEY JG, BRADLEY JL, BLAMIRE AM, MANNERS D, STYLES P, SCHAPIRA AH, COOPER JM. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol. 2001;49:590–596. PubMed

LUCCHETTI J, MARINO M, PAPA S, TORTAROLO M, GUISO G, POZZI S, BONETTO V, CACCIA S, BEGHI E, BENDOTTI C, GOBBI M. A mouse model of familial ALS has increased CNS levels of endogenous ubiquinol9/10 and does not benefit from exogenous administration of ubiquinol10. PLoS One. 2013;8:e69540. doi: 10.1371/journal.pone.0069540. Published 2013 Jul 23. PubMed DOI PMC

LYNCH DR, PERLMAN SL, MEIER T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol. 2010;67:941–947. doi: 10.1001/archneurol.2010.168. PubMed DOI

MANCZAK M, MAO P, CALKINS MJ, CORNEA A, REDDY AP, MURPHY MP, SZETO HH, PARK B, REDDY PH. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons. J Alzheimers Dis. 2010;20(Suppl 2):S609–S631. doi: 10.3233/JAD-2010-100564. PubMed DOI PMC

MANTLE D, DYBRING A. Bioavailability of coenzyme Q10: An overview of the absorption process and subsequent metabolism. Antioxidants (Basel) 2020;9:386. doi: 10.3390/antiox9050386. PubMed DOI PMC

MANYEVITCH R, PROTAS M, SCARPIELLO S, DELISO M, BASS B, NANAJIAN A, CHANG M, THOMPSON SM, KHOURY N, GONNELLA R, TROTZ M, MOORE DB, HARMS E, PERRY G, CLUNES L, ORTIZ A, FRIEDRICH JO, MURRAY IVJ. Evaluation of metabolic and synaptic dysfunction hypotheses of Alzheimer’s disease (AD): A meta-analysis of CSF markers. Curr Alzheimer Res. 2018;15:164–181. doi: 10.2174/1567205014666170921122458. PubMed DOI PMC

MAO P, MANCZAK M, SHIRENDEB UP, REDDY PH. MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim Biophys Acta. 2013;1832:2322–2331. doi: 10.1016/j.bbadis.2013.09.005. PubMed DOI PMC

MARIOTTI C, SOLARI A, TORTA D, MARANO L, FIORENTINI C, DI DONATO S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology. 2003;60:1676–1679. doi: 10.1212/01.wnl.0000055872.50364.fc. PubMed DOI

MARX W, HOCKEY M, MCGUINNESS AJ, LANE M, CHRISTODOULOU J, VAN DER MEI I, BERK M, DEAN OM, TAYLOR B, PONSONBY A-L, THE RELIEF TEAM. The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. Mult Scler Relat Disord. 2020;37:101486. doi: 10.1016/j.msard.2019.101486. PubMed DOI

MATSUBARA T, AZUMA T, YOSHIDA S, YAMAGAMI T. Serum coenzyme Q10 level in Parkinson syndrome. In: Folkers K, Littarru GP, Yamagami T, editors. Biomedical and clinical aspects of coenzyme Q10. New York: Elsevier Science; 1991. pp. 159–166.

MATTHEWS RT, YANG L, BROWNE S, BAIK M, BEAL MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95:8892–8897. doi: 10.1073/pnas.95.15.8892. PubMed DOI PMC

MATTILA P, KUMPULAINEN J. Coenzymes Q9 and Q10: Contents in foods and dietary intake. J Food Compost Anal. 2001;14:409–417. doi: 10.1006/jfca.2000.0983. DOI

MAUSKOP A. Nonmedication, alternative, and complementary treatments for migraine. Continuum (Minneap Minn) 2012;18:796–806. doi: 10.1212/01.CON.0000418643.24408.40. PubMed DOI

McCARTHY S, SOMAYAJULU M, SIKORSKA M, BOROWY-BOROWSKI H, PANDEY S. Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble coenzyme Q10. Toxicol Appl Pharmacol. 2004;201:21–31. doi: 10.1016/j.taap.2004.04.019. PubMed DOI

McCOY MK, COOKSON MR. Mitochondrial quality control and dynamics in Parkinson’s disease. Antioxid Redox Signal. 2012;16:869–882. doi: 10.1089/ars.2011.4019. PubMed DOI PMC

McGARRY A, MCDERMOTT M, KIEBURTZ K, ET AL. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88:152–159. doi: 10.1212/WNL.0000000000003478. PubMed DOI PMC

McMANUS MJ, MURPHY MP, FRANKLIN JL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2011;31:15703–15715. doi: 10.1523/JNEUROSCI.0552-11.2011. PubMed DOI PMC

MEIER T, PERLMAN SL, RUMMEY C, COPPARD NJ, LYNCH DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012;259:284–291. doi: 10.1007/s00415-011-6174-y. PubMed DOI

MENALLED LB, PATRY M, RAGLAND N, LOWDEN PA, GOODMAN J, MINNICH J, ZAHASKY B, PARK L, LEEDS J, HOWLAND D, SIGNER E, TOBIN AJ, BRUNNER D. Comprehensive behavioral testing in the R6/2 mouse model of Huntington’s disease shows no benefit from CoQ10 or minocycline. PLoS One. 2010;5:e9793. doi: 10.1371/journal.pone.0009793. PubMed DOI PMC

MIQUEL E, CASSINA A, MARTÍNEZ-PALMA L, SOUZA JM, BOLATTO C, RODRÍGUEZ-BOTTERO S, LOGAN A, SMITH RA, MURPHY MP, BARBEITO L, RADI R, CASSINA P. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med. 2014;70:204–213. doi: 10.1016/j.freeradbiomed.2014.02.019. PubMed DOI

MISCHLEY LK, ALLEN J, BRADLEY R. Coenzyme Q10 deficiency in patients with Parkinson’s disease. J Neurol Sci. 2012;318:72–75. doi: 10.1016/j.jns.2012.03.023. PubMed DOI PMC

MIZUNO Y, OHTA S, TANAKA M, TAKAMIYA S, SUZUKI K, SATO T, OYA H, OZAWA T, KAGAWA Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun. 1989;163:1450–1455. doi: 10.1016/0006-291x(89)91141-8. PubMed DOI

MOCCIA M, CAPACCHIONE A, LANZILLO R, CARBONE F, MICILLO T, PERNA F, DE ROSA A, CAROTENUTO A, ALBERO R, MATARESE G, PALLADINO R, BRESCIA MORRA V. Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286418819074. doi: 10.1177/1756286418819074. PubMed DOI PMC

MOLINA J, DE BUSTOS F, JIMÉNEZ-JIMÉNEZ FJ, GÓMEZ-ESCALONILLA C, GARCÍA-REDONDO A, ESTEBAN J, GUERRERO-SOLA A, DEL HOYO P, MARTÍNEZ-SALIO A, RAMÍREZ-RAMOS C, INDURAIN GR, ARENAS J. Serum levels of coenzyme Q10 in patients with amyotrophic lateral sclerosis. J Neural Transm. 2000;107:1021–1026. doi: 10.1007/s007020070050. PubMed DOI

MOLLET J, GIURGEA I, SCHLEMMER D, DALLNER G, CHRETIEN D, DELAHODDE A, BACQ D, DE LONLAY P, MUNNICH A, RÖTIG A. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest. 2007;117:765–772. doi: 10.1172/JCI29089. PubMed DOI PMC

MONTENEGRO L, TURNATURI R, PARENTI C, PASQUINUCCI L. Idebenone: Novel strategies to improve its systemic and local efficacy. Nanomaterials (Basel) 2018;8:87. doi: 10.3390/nano8020087. PubMed DOI PMC

MÜLLER T, BÜTTNER T, GHOLIPOUR AF, KUHN W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci Lett. 2003;341:201–204. doi: 10.1016/s0304-3940(03)00185-x. PubMed DOI

MURPHY MP, SMITH RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629–656. doi: 10.1146/annurev.pharmtox.47.120505.105110. PubMed DOI

MUSCOLI C, FRESTA M, CARDILE V, PALUMBO M, RENIS M, PUGLISI G, PAOLINO D, NISTICÒ S, ROTIROTI D, MOLLACE V. Ethanol-induced injury in rat primary cortical astrocytes involves oxidative stress: effect of idebenone. Neurosci Lett. 2002;329:21–24. doi: 10.1016/s0304-3940(02)00567-0. PubMed DOI

MUTHUKUMARAN K, KANWAR A, VEGH C, MARGINEAN A, ELLIOTT A, GUILBEAULT N, BADOUR A, SIKORSKA M, COHEN J, PANDEY S. Ubisol-Q10 (a nanomicellar water-soluble formulation of CoQ10) treatment inhibits Alzheimer-type behavioral and pathological symptoms in a double transgenic mouse (TgAPEswe, PSEN1dE9) model of Alzheimer’s dsease. J Alzheimers Dis. 2018;61:221–236. doi: 10.3233/JAD-170275. PubMed DOI

MUTHUKUMARAN K, LEAHY S, HARRISON K, SIKORSKA M, SANDHU JK, COHEN J, KESHAN C, LOPATIN D, MILLER H, BOROWY-BOROWSKI H, LANTHIER P, WEINSTOCK S, PANDEY S. Orally delivered water soluble coenzyme Q10 (Ubisol-Q10) blocks on-going neurodegeneration in rats exposed to paraquat: potential for therapeutic application in Parkinson’s disease. BMC Neurosci. 2014a;15:21. doi: 10.1186/1471-2202-15-21. PubMed DOI PMC

MUTHUKUMARAN K, SMITH J, JASRA H, SIKORSKA M, SANDHU JK, COHEN J, LOPATIN D, PANDEY S. Genetic susceptibility model of Parkinson’s disease resulting from exposure of DJ-1 deficient mice to MPTP: evaluation of neuroprotection by Ubisol-Q10. J Parkinsons Dis. 2014b;4:523–530. doi: 10.3233/JPD-140368. PubMed DOI

NAGASE M, YAMAMOTO Y, MATSUMOTO N, ARAI Y, HIROSE N. Increased oxidative stress and coenzyme Q10 deficiency in centenarians. J Clin Biochem Nutr. 2018;63:129–136. doi: 10.3164/jcbn.17-124. PubMed DOI PMC

NAGASE M, YAMAMOTO Y, MIYAZAKI Y, YOSHINO H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21:104–112. doi: 10.1179/1351000215Y.0000000026. PubMed DOI PMC

NEGIDA A, MENSHAWY A, EL ASHAL G, ELFOULY Y, HANI Y, HEGAZY Y, EL GHONIMY S, FOUDA S, RASHAD Y. Coenzyme Q10 for patients with Parkinson’s disease: A systematic review and meta-analysis. CNS Neurol Disord Drug Targets. 2016;15:45–53. doi: 10.2174/1871527314666150821103306. PubMed DOI

NIKLOWITZ P, ONUR S, FISCHER A, LAUDES M, PALUSSEN M, MENKE T, DÖRING F. Coenzyme Q10 serum concentration and redox status in European adults: influence of age, sex, and lipoprotein concentration. J Clin Biochem Nutr. 2016;58:240–245. doi: 10.3164/jcbn.15-73. PubMed DOI PMC

OCHIAI A, ITAGAKI S, KUROKAWA T, KOBAYASHI M, HIRANO T, ISEKI K. Improvement in intestinal coenzyme Q10 absorption by food intake. Yakugaku Zasshi. 2007;127:1251–1254. doi: 10.1248/yakushi.127.1251. PubMed DOI

OERTEL W, SCHULZ JB. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem. 2016;139(Suppl 1):325–337. doi: 10.1111/jnc.13750. PubMed DOI

OGASAHARA S, ENGEL AG, FRENS D, MACK D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379–2382. doi: 10.1073/pnas.86.7.2379. PubMed DOI PMC

ONUR S, NIKLOWITZ P, FISCHER A, METGES CC, GRUNE T, MENKE T, RIMBACH G, DÖRING F. A comparative study into alterations of coenzyme Q redox status in ageing pigs, mice, and worms. Biofactors. 2014;40:346–354. doi: 10.1002/biof.1160. PubMed DOI

OTEIZA PI, UCHITEL OD, CARRASQUEDO F, DUBROVSKI AL, ROMA JC, FRAGA CG. Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res. 1997;22:535–539. doi: 10.1023/a:1027384432715. PubMed DOI

PALAMAKULA A, SOLIMAN M, KHAN MM. Regional permeability of coenzyme Q10 in isolated rat gastrointestinal tracts. Pharmazie. 2005;60:212–214. PubMed

PARKER WD, JR, PARKS JK, SWERDLOW RH. Complex I deficiency in Parkinson’s disease frontal cortex. Brain Res. 2008;1189:215–218. doi: 10.1016/j.brainres.2007.10.061. PubMed DOI PMC

PARKINSON MH, SCHULZ JB, GIUNTI P. Co-enzyme Q10 and idebenone use in Friedreich’s ataxia. J Neurochem. 2013;126(Suppl 1):125–141. doi: 10.1111/jnc.12322. PubMed DOI

PARKINSON STUDY GROUP QE3 INVESTIGATORS et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71:543–552. doi: 10.1001/jamaneurol.2014.131. PubMed DOI

PAROHAN M, SARRAF P, JAVANBAKHT MH, FOROUSHANI AR, RANJI-BURACHALOO S, DJALALI M. The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Nutr Neurosci. 2021;24:317–326. doi: 10.1080/1028415X.2019.1627770. PubMed DOI

PAROHAN M, SARRAF P, JAVANBAKHT MH, RANJI-BURACHALOO S, DJALALI M. Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Neurosci. 2020;23:868–875. doi: 10.1080/1028415X.2019.1572940. PubMed DOI

PASTOR-MALDONADO CJ, SUÁREZ-RIVERO JM, POVEA-CABELLO S, ÁLVAREZ-CÓRDOBA M, VILLALÓN-GARCÍA I, MUNUERA-CABEZA M, SUÁREZ-CARRILLO A, TALAVERÓN-REY M, SÁNCHEZ-ALCÁZAR JA. Coenzyme Q10: Novel Formulations and Medical Trends. Int J Mol Sci. 2020;21:8432. doi: 10.3390/ijms21228432. PubMed DOI PMC

POTGIETER M, PRETORIUS E, PEPPER MS. Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutr Rev. 2013;71:180–188. doi: 10.1111/nure.12011. PubMed DOI

PRAVST I, RODRÍGUEZ AGUILERA JC, CORTES RODRIGUEZ AB, JAZBAR J, LOCATELLI I, HRISTOV H, ŽMITEK K. Comparative bioavailability of different coenzyme Q10 formulations in healthy elderly individuals. Nutrients. 2020;12 doi: 10.3390/nu12030784. pii: E784. PubMed DOI PMC

PRAVST I, ZMITEK K, ZMITEK J. Coenzyme Q10 contents in foods and fortification strategies. Crit Rev Food Sci Nutr. 2010;50:269–280. doi: 10.1080/10408390902773037. PubMed DOI

PRZEDBORSKI S, TIEU K, PERIER C, VILA M. MPTP as a mitochondrial neurotoxic model of Parkinson’s disease. J Bioenerg Biomembr. 2004;36:375–379. doi: 10.1023/B:JOBB.0000041771.66775.d5. PubMed DOI

PYO Y. Coenzyme Q10 and Q9 contents in 6 commercial vegetable oils and their average daily intakes in Korea. Food Sci Biotechnol. 2010;9:837–841. doi: 10.1007/s10068-010-0118-7. DOI

QUINZII C, NAINI A, SALVIATI L, TREVISSON E, NAVAS P, DIMAURO S, HIRANO M. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet. 2006;78:345–349. doi: 10.1086/500092. PubMed DOI PMC

QUINZII CM, LUNA-SANCHEZ M, ZIOSI M, HIDALGO-GUTIERREZ A, KLEINER G, LOPEZ LC. The role of sulfide oxidation impairment in the pathogenesis of primary CoQ deficiency. Front Physiol. 2017;8:525. doi: 10.3389/fphys.2017.00525. PubMed DOI PMC

RAIZNER AE. Coenzyme Q10. Methodist Debakey Cardiovasc J. 2019;15:185–191. doi: 10.14797/mdcj-15-3-185. PubMed DOI PMC

RAMASARMA T. Natural occurrence and distribution of coenzyme Q. In: Lenaz G, editor. Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone. Wiley & Sons; Chichester: 1985. pp. 67–81.

RANEN NG, PEYSER CE, COYLE JT, BYLSMA FW, SHERR M, DAY L, FOLSTEIN MF, BRANDT J, ROSS CA, FOLSTEIN SE. A controlled trial of idebenone in Huntington’s disease. Mov Disord. 1996;11:549–554. doi: 10.1002/mds.870110510. PubMed DOI

RAUCHOVÁ H, BATTINO M, FATO R, LENAZ G, DRAHOTA Z. Coenzyme Q-pool function in glycerol-3-phosphate oxidation in hamster brown adipose tissue mitochondria. J Bioenerg Biomembr. 1992;24:235–241. doi: 10.1007/BF00762682. PubMed DOI

RAUCHOVÁ H, DRAHOTA Z, BERGAMINI C, FATO R, LENAZ G. Modification of respiratory-chain enzyme activities in brown adipose tissue mitochondria by idebenone (hydroxydecyl-ubiquinone) J Bioenerg Biomembr. 2008;40:85–93. doi: 10.1007/s10863-008-9134-1. PubMed DOI

RAUCHOVÁ H, FATO R, DRAHOTA Z, LENAZ G. Steady-state kinetics of reduction of coenzyme Q analogs by glycerol-3-phosphate dehydrogenase in brown adipose tissue mitochondria. Arch Biochem Biophys. 1997;344:235–241. doi: 10.1006/abbi.1997.0150. PubMed DOI

RAUCHOVÁ H, VOKURKOVÁ M. Recent view of coenzyme Q. Chem Listy. 2009;103:32–39. (In Czech)

RAUCHOVÁ H, VOKURKOVÁ M, DRAHOTA Z. Idebenone-induced recovery of glycerol-3-phosphate and succinate oxidation inhibited by digitonin. Physiol Res. 2012;61:259–265. doi: 10.33549/physiolres.932318. PubMed DOI

RAUCHOVÁ H, VRBACKÝ M, BERGAMINI C, FATO R, LENAZ G, HOUSTEK J, DRAHOTA Z. Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone. Biochem Biophys Res Commun. 2006;339:362–366. doi: 10.1016/j.bbrc.2005.11.035. PubMed DOI

REIS RAG, CALIL FA, FELICIANO PR, PINHEIRO MP, NONATO MC. The dihydroorotate dehydrogenases: Past and present. Arch Biochem Biophys. 2017;632:175–191. doi: 10.1016/j.abb.2017.06.019. PubMed DOI

RINALDI C, TUCCI T, MAIONE S, GIUNTA A, DE MICHELE G, FILLA A. Low-dose idebenone treatment in Friedreich’s ataxia with and without cardiac hypertrophy. J Neurol. 2009;256:1434–1437. doi: 10.1007/s00415-009-5130-6. PubMed DOI

ROSENFELDT FL, HAAS SJ, KRUM H, HADJ A, NG K, LEONG JY, WATTS GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21:297–306. doi: 10.1038/sj.jhh.1002138. PubMed DOI

RÖTIG A, APPELKVIST EL, GEROMEL V, CHRETIEN D, KADHOM N, EDERY P, LEBIDEAU M, DALLNER G, MUNNICH A, ERNSTER L, RUSTIN P. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet. 2000;356(9227):391–395. doi: 10.1016/S0140-6736(00)02531-9. PubMed DOI

ROZEN TD, OSHINSKY ML, GEBELINE CA, BRADLEY KC, YOUNG WB, SHECHTER AL, SILBERSTEIN SD. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002;22:137–141. doi: 10.1046/j.1468-2982.2002.00335.x. PubMed DOI

RUSTIN P, VON KLEIST-RETZOW JC, CHANTREL-GROUSSARD K, SIDI D, MUNNICH A, RÖTIG A. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. Lancet. 1999;354(9177):477–479. doi: 10.1016/S0140-6736(99)01341-0. PubMed DOI

SÁNDOR PS, DI CLEMENTE L, COPPOLA G, SAENGER U, FUMAL A, MAGIS D, SEIDEL L, AGOSTI RM, SCHOENEN J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64:713–715. doi: 10.1212/01.WNL.0000151975.03598.ED. PubMed DOI

SANOOBAR M, EGHTESADI S, AZIMI A, KHALILI M, JAZAYERI S, REZA GOHARI M. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis. Int J Neurosci. 2013;123:776–782. doi: 10.3109/00207454.2013.801844. PubMed DOI

SANOOBAR M, EGHTESADI S, AZIMI A, KHALILI M, KHODADADI B, JAZAYERI S, GOHARI MR, ARYAEIAN N. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. 2015;18:169–176. doi: 10.1179/1476830513Y.0000000106. PubMed DOI

SANOOBAR M, DEHGHAN P, KHALILI M, AZIMI A, SEIFAR F. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clinical trial. Nutr Neurosci. 2016;19:138–143. doi: 10.1179/1476830515Y.0000000002. PubMed DOI

SCHAPIRA AH, COOPER JM, DEXTER D, CLARK JB, JENNER P, MARSDEN CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990a;54:823–827. doi: 10.1111/j.1471-4159.1990.tb02325.x. PubMed DOI

SCHAPIRA AH, MANN VM, COOPER JM, DEXTER D, DANIEL SE, JENNER P, CLARK JB, MARSDEN CD. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem. 1990b;55:2142–2145. doi: 10.1111/j.1471-4159.1990.tb05809.x. PubMed DOI

SCHILLING G, COONFIELD ML, ROSS CA, BORCHELT DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington’s disease transgenic mouse model. Neurosci Lett. 2001;315:149–153. doi: 10.1016/s0304-3940(01)02326-6. PubMed DOI

SCHMELZER C, LINDNER I, RIMBACH G, NIKLOWITZ P, MENKE T, DÖRING F. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors. 2008;32:179–183. doi: 10.1002/biof.5520320121. PubMed DOI

SCHMELZER C, LINDNER I, VOCK C, FUJII K, DÖRING F. Functional connections and pathways of coenzyme Q10-inducible genes: an in-silico study. IUBMB Life. 2007;59:628–633. doi: 10.1080/15216540701545991. PubMed DOI

SENIN U, PARNETTI L, BARBAGALLO-SANGIORGI G, BARTORELLI L, BOCOLA V, CAPURSO A, CUZZUPOLI M, DENARO M, MARIGLIANO V, TAMMARO AE, FIORAVANTI M. Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr. 1992;15:249–260. doi: 10.1016/0167-4943(92)90060-h. PubMed DOI

SHERER TB, BETARBET R, TESTA CM, SEO BB, RICHARDSON JR, KIM JH, MILLER GW, YAGI T, MATSUNO-YAGI A, GREENAMYRE JT. Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci. 2003;23:10756–10764. doi: 10.1523/JNEUROSCI.23-34-10756.2003. PubMed DOI PMC

SHULTS CW, HAAS RH, PASSOV D, BEAL MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997;42:261–264. doi: 10.1002/ana.410420221. PubMed DOI

SHULTS CW, OAKES D, KIEBURTZ K, BEAL MF, HAAS R, PLUMB S, JUNCOS JL, NUTT J, SHOULSON I, CARTER J, KOMPOLITI K, PERLMUTTER JS, REICH S, STERN M, WATTS RL, KURLAN R, MOLHO E, HARRISON M, LEW M PARKINSON STUDY GROUP. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541–1550. doi: 10.1001/archneur.59.10.1541. PubMed DOI

SINGH RB, NIAZ MA, KUMAR A, SINDBERG CD, MOESGAARD S, LITTARRU GP. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors. 2005;25:219–224. doi: 10.1002/biof.5520250127. PubMed DOI

SLATER SK, NELSON TD, KABBOUCHE MA, LECATES SL, HORN P, SEGERS A, MANNING P, POWERS SW, HERSHEY AD. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011;31:897–905. doi: 10.1177/0333102411406755. PubMed DOI

SMITH EF, SHAW PJ, DE VOS KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052. PubMed DOI

SMITH KM, MATSON S, MATSON WR, CORMIER K, DEL SIGNORE SJ, HAGERTY SW, STACK EC, RYU H, FERRANTE RJ. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington’s disease mice. Biochim Biophys Acta. 2006;1762:616–626. doi: 10.1016/j.bbadis.2006.03.004. PubMed DOI

SMITH RA, MURPHY MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96–103. doi: 10.1111/j.1749-6632.2010.05627.x. PubMed DOI

SOCHOCKA M, ZWOLIŃSKA K, LESZEK J. The infectious etiology of Alzheimer’s disease. Curr Neuropharmacol. 2017;15:996–1009. doi: 10.2174/1570159X15666170313122937. PubMed DOI PMC

SÖDERBERG M, EDLUND C, ALAFUZOFF I, KRISTENSSON K, DALLNER G. Lipid composition in different regions of the brain in Alzheimer’s disease/senile dementia of Alzheimer’s type. J Neurochem. 1992;59:1646–1653. doi: 10.1111/j.1471-4159.1992.tb10994.x. PubMed DOI

SOHAL RS, KAMZALOV S, SUMIEN N, FERGUSON M, REBRIN I, HEINRICH KR, FORSTER MJ. Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice. Free Radic Biol Med. 2006;40:480–487. doi: 10.1016/j.freeradbiomed.2005.08.037. PubMed DOI PMC

SOHMIYA M, TANAKA M, SUZUKI Y, TANINO Y, OKAMOTO K, YAMAMOTO Y. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci. 2005;228:49–53. doi: 10.1016/j.jns.2004.09.030. PubMed DOI

SOLEIMANI M, JAMEIE SB, BARATI M, MEHDIZADEH M, KERDARI M. Effects of coenzyme Q10 on the ratio of TH1/TH2 in experimental autoimmune encephalomyelitis model of multiple sclerosis in C57BL/6. Iran Biomed J. 2014;18:203–211. doi: 10.6091/ibj.13362.2014. PubMed DOI PMC

SOLESIO ME, PRIME TA, LOGAN A, MURPHY MP, DEL MAR ARROYO-JIMENEZ M, JORDÁN J, GALINDO MF. The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson’s disease. Biochim Biophys Acta. 2013;1832:174–182. doi: 10.1016/j.bbadis.2012.07.009. PubMed DOI

SPARACO M, FELEPPA M, LIPTON RB, RAPOPORT AM, BIGAL ME. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia. 2006;26:361–372. doi: 10.1111/j.1468-2982.2005.01059.x. PubMed DOI

SPINDLER M, BEAL MF, HENCHCLIFFE C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2009;5:597–610. doi: 10.2147/ndt.s5212. PubMed DOI PMC

STACK EC, SMITH KM, RYU H, CORMIER K, CHEN M, HAGERTY SW, DEL SIGNORE SJ, CUDKOWICZ ME, FRIEDLANDER RM, FERRANTE RJ. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington’s disease mice. Biochim Biophys Acta. 2006;1762:373–380. doi: 10.1016/j.bbadis.2005.11.002. PubMed DOI

STANGA S, CARETTO A, BOIDO M, VERCELLI A. Mitochondrial dysfunctions: A red thread across neurodegenerative diseases. Int J Mol Sci. 2020;21:E3719. doi: 10.3390/ijms21103719. PubMed DOI PMC

STEFELY JA, PAGLIARINI DJ. Biochemistry of mitochondrial coenzyme Q biosynthesis. Trends Biochem Sci. 2017;42:824–843. doi: 10.1016/j.tibs.2017.06.008. PubMed DOI PMC

STRIJKS E, KREMER HP, HORSTINK MW. Q10 therapy in patients with idiopathic Parkinson’s disease. Mol Aspects Med. 1997;18(Suppl):S237–S240. doi: 10.1016/s0098-2997(97)00008-3. PubMed DOI

SVED AF, ITO S, SVED JC. Brainstem mechanisms of hypertension: role of the rostral ventrolateral medulla. Curr Hypertens Rep. 2003;5:262–268. doi: 10.1007/s11906-003-0030-0. PubMed DOI

TAI MH, WANG LL, WU KL, CHAN JY. Increased superoxide anion in rostral ventrolateral medulla contributes to hypertension in spontaneously hypertensive rats via interactions with nitric oxide. Free Radic Biol Med. 2005;38:450–462. doi: 10.1016/j.freeradbiomed.2004.11.015. PubMed DOI

TAKAHASHI M, TAKAHASHI K. Water-soluble CoQ10 as a promising anti-aging agent for neurological dysfunction in brain mitochondria. Antioxidants (Basel) 2019;8:61. doi: 10.3390/antiox8030061. PubMed DOI PMC

TASSET I, AGÜERA E, SÁNCHEZ-LÓPEZ F, FEIJÓO M, GIRALDO AI, CRUZ AH, GASCÓN F, TÚNEZ I. Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem. 2012;45:440–444. doi: 10.1016/j.clinbiochem.2012.01.023. PubMed DOI

THAL LJ, GRUNDMAN M, BERG J, ERNSTROM K, MARGOLIN R, PFEIFFER E, WEINER MF, ZAMRINI E, THOMAS RG. Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology. 2003;61:1498–1502. doi: 10.1212/01.wnl.0000096376.03678.c1. PubMed DOI

TIEU K. A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb Perspect Med. 2011;1(1):a009316. doi: 10.1101/cshperspect.a009316. PubMed DOI PMC

TOBORE TO. Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington’s disease. J Neurosci Res. 2019;97:1455–1468. doi: 10.1002/jnr.24492. PubMed DOI

TRUMPOWER BL. New concepts on the role of ubiquinone in the mitochondrial respiratory chain. J Bioenerg Biomembr. 1981;13:1–24. doi: 10.1007/BF00744743. PubMed DOI

VEGH C, PUPULIN S, WEAR D, CULMONE L, HUGGARD R, MA D, PANDEY S. Resumption of autophagy by Ubisol-Q10 in presenilin-1 mutated fibroblasts and transgenic AD mice: Implications for inhibition of senescence and neuroprotection. Oxid Med Cell Longev. 2019;2019:7404815. doi: 10.1155/2019/7404815. PubMed DOI PMC

VOS T, FLAXMAN AD, NAGHAVI M, LOZANO R, MICHAUD C, EZZATI M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196. doi: 10.1016/S0140-6736(12)61729-2. PubMed DOI PMC

WADA H, GOTO H, HAGIWARA S, YAMAMOTO Y. Redox status of coenzyme Q10 is associated with chronological age. J Am Geriatr Soc. 2007;55:1141–1142. doi: 10.1111/j.1532-5415.2007.01209.x. PubMed DOI

WADSWORTH TL, BISHOP JA, PAPPU AS, WOLTJER RL, QUINN JF. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer’s disease. J Alzheimers Dis. 2008;14:225–234. doi: 10.3233/jad-2008-14210. PubMed DOI PMC

WAINWRIGHT L, HARGREAVES IP, GEORGIAN AR, TURNER C, DALTON RN, ABBOTT NJ, HEALES SJR, PRESTON JE. CoQ10 deficient endothelial cell culture model for the investigation of CoQ10 blood-brain barrier transport. J Clin Med. 2020;9:3236. doi: 10.3390/jcm9103236. PubMed DOI PMC

WALTER L, MIYOSHI H, LEVERVE X, BERNARD P, FONTAINE E. Regulation of the mitochondrial permeability transition pore by ubiquinone analogs. A progress report. Free Radic Res. 2002;36:405–412. doi: 10.1080/10715760290021252. PubMed DOI

WANG Y, HEKIMI S. Molecular genetics of ubiquinone biosynthesis in animals. Crit Rev Biochem Mol Biol. 2013;48:69–88. doi: 10.3109/10409238.2012.741564. PubMed DOI PMC

WANG W, ZHAO F, MA X, PERRY G, ZHU X. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Mol Neurodegener. 2020;15:30. doi: 10.1186/s13024-020-00376-6. PubMed DOI PMC

WANG Z, BAI Z, QIN X, CHENG Y. Aberrations in oxidative stress markers in amyotrophic lateral sclerosis: A systematic review and meta-analysis. Oxid Med Cell Longev. 2019;2019:1712323. doi: 10.1155/2019/1712323. PubMed DOI PMC

WATMOUGH NJ, FRERMAN FE. The electron transfer flavoprotein: ubiquinone oxidoreductases. Biochim Biophys Acta. 2010;1797:1910–1916. doi: 10.1016/j.bbabio.2010.10.007. PubMed DOI

WEBER C, BYSTED A, HØLMER G. Coenzyme Q10 in the diet--daily intake and relative bioavailability. Mol Aspects Med. 1997a;18(Suppl):S251–254. doi: 10.1016/S0098-2997(97)00003-4. PubMed DOI

WEBER C, BYSTED A, HØLMER G. The coenzyme Q10 content of the average Danish diet. Int J Vitam Nutr Res. 1997b;67:123–129. PubMed

WITTE ME, NIJLAND PG, DREXHAGE JA, GERRITSEN W, GEERTS D, VAN HET HOF B, REIJERKERK A, DE VRIES HE, VAN DER VALK P, VAN HORSSEN J. Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol. 2013;125:231–243. doi: 10.1007/s00401-012-1052-y. PubMed DOI

WOLDEAMANUEL YW, COWAN RP. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–315. doi: 10.1016/j.jns.2016.11.071. PubMed DOI

WU KL, CHAO YM, TSAY SJ, CHEN CH, CHAN SH, DOVINOVA I, CHAN JY. Role of nitric oxide synthase uncoupling at rostral ventrolateral medulla in redox-sensitive hypertension associated with metabolic syndrome. Hypertension. 2014;64:815–824. doi: 10.1161/HYPERTENSIONAHA.114.03777. PubMed DOI

XI Y, FENG D, TAO K, WANG R, SHI Y, QIN H, MURPHY MP, YANG Q, ZHAO G. MitoQ protects dopaminergic neurons in a 6-OHDA induced PD model by enhancing Mfn2-dependent mitochondrial fusion via activation of PGC-1α. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2859–2870. doi: 10.1016/j.bbadis.2018.05.018. PubMed DOI

YANG L, CALINGASAN NY, WILLE EJ, CORMIER K, SMITH K, FERRANTE RJ, BEAL MF. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J Neurochem. 2009;109:1427–1439. doi: 10.1111/j.1471-4159.2009.06074.x. PubMed DOI PMC

YANG X, YANG Y, LI G, WANG J, YANG ES. Coenzyme Q10 attenuates β-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol Neurosci. 2008;34:165–171. doi: 10.1007/s12031-007-9033-7. PubMed DOI

YOUNG ML, FRANKLIN JL. The mitochondria-targeted antioxidant MitoQ inhibits memory loss, neuropathology, and extends lifespan in aged 3xTg-AD mice. Mol Cell Neurosci. 2019;101:103409. doi: 10.1016/j.mcn.2019.103409. PubMed DOI PMC

YORITAKA A, KAWAJIRI S, YAMAMOTO Y, NAKAHARA T, ANDO M, HASHIMOTO K, NAGASE M, SAITO Y, HATTORI N. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:911–916. doi: 10.1016/j.parkreldis.2015.05.022. PubMed DOI

YORNS WR, JR, HARDISON HH. Mitochondrial dysfunction in migraine. Semin Pediatr Neurol. 2013;20:188–193. doi: 10.1016/j.spen.2013.09.002. PubMed DOI

YU M, BEGA D. A review of the clinical evidence for complementary and alternative medicine in Huntington’s disease. Tremor Other Hyperkinet Mov (N Y) 2019 Aug 26;9 doi: 10.7916/tohm.v0.678. PubMed DOI PMC

YU MH, TSANG MH, LAI S, HO MS, TSE DML, WILLIS B, KWONG AK, CHOU YY, LIN SP, QUINZII CM, HWU WL, CHIEN YH, KUO PL, CHAN VC, TSOI C, CHONG SC, RODENBURG RJT, SMEITINK J, MAK CC, YEUNG KS, FUNG JL, LAM W, HUI J, LEE NC, FUNG CW, CHUNG BH. Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese. NPJ Genom Med. 2019;4:18. doi: 10.1038/s41525-019-0091-x. PubMed DOI PMC

YUBERO D, MONTERO R, MARTÍN MA, MONTOYA J, RIBES A, GRAZINA M, TREVISSON E, RODRIGUEZ-AGUILERA JC, HARGREAVES IP, SALVIATI L, NAVAS P, ARTUCH R, JOU C, JIMENEZ-MALLEBRERA C, NASCIMENTO A, PÉREZ-DUEÑAS B, ORTEZ C, RAMOS F, COLOMER J, O’CALLAGHAN M, PINEDA M, GARCÍA-CAZORLA A, ESPINÓS C, RUIZ A, MACAYA A, MARCÉ-GRAU A, GARCIA-VILLORIA J, ARIAS A, EMPERADOR S, RUIZ-PESINI E, LOPEZ-GALLARDO E, NEERGHEEN V, SIMÕES M, DIOGO L, BLÁZQUEZ A, GONZÁLEZ-QUINTANA A, DELMIRO A, DOMÍNGUEZ-GONZÁLEZ C, ARENAS J, GARCÍA-SILVA MT, MARTÍN E, QUIJADA P, HERNÁNDEZ-LAÍN A, MORÁN M, RIVAS INFANTE E, ÁVILA POLO R, PARADAS LÓPE C, BAUTISTA LORITE J, MARTÍNEZ FERNÁNDEZ EM, CORTÉS AB, SÁNCHEZ-CUESTA A, CASCAJO MV, ALCÁZAR M, BREA-CALVO G. Secondary coenzyme Q10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders. Mitochondrion. 2016;30:51–58. doi: 10.1016/j.mito.2016.06.007. PubMed DOI

ZAHEDNASAB H, MESBAH-NAMIN SA, BALOOD M. Coenzyme Q10 supplementation and multiple sclerosis. Nutr Neurosci. 2015;18:192. doi: 10.1179/1476830514Y.0000000126. PubMed DOI

ZENG Z, LI Y, LU S, HUANG W, DI W. Efficacy of CoQ10 as supplementation for migraine. A meta-analysis. Acta Neurol Scand. 2019;139:284–293. doi: 10.1111/ane.13051. PubMed DOI

ZHAI J, BO Y, LU Y, LIU C, ZHANG L. Effects of coenzyme Q10 on markers of inflammation: A systematic review and meta-analysis. PLoS One. 2017;12:e0170172. doi: 10.1371/journal.pone.0170172. PubMed DOI PMC

ZHANG Y, ABERG F, APPELKVIST EL, DALLNER G, ERNSTER L. Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr. 1995;125:446–453. doi: 10.1093/jn/125.3.446. PubMed DOI

ZHANG Y, APPELKVIST EL, KRISTENSSON K, DALLNER G. The lipid compositions of different regions of rat brain during development and aging. Neurobiol Aging. 1996;17:869–875. doi: 10.1016/s0197-4580(96)00076-0. PubMed DOI

ZHU ZG, SUN MX, ZHANG WL, WANG WW, JIN YM, XIE CL. The efficacy and safety of coenzyme Q10 in Parkinson’s disease: a meta-analysis of randomized controlled trials. Neurol Sci. 2017;38:215–224. doi: 10.1007/s10072-016-2757-9. PubMed DOI

ZS-NAGY I. Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review. Arch Gerontol Geriatr. 1990;11:177–186. doi: 10.1016/0167-4943(90)90063-c. PubMed DOI

ZULIANI C, BARONI L . COQ DEFICIENCY STUDY GROUP. Antioxidants for the prevention and treatment of multiple sclerosis: An overview. In: Watson R, Preedy V, editors. Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease. Elsevier; 2015. pp. 341–353. DOI

CoQ10 and Mitochondrial Dysfunction in Alzheimer's Disease

Mitochondria in human reproduction: novel paradigm in the onset of neurodegenerative disorders